Figure 3:Effects of the oral treatment with LASSBio-1366 (50 mg/kg/day) for 2 weeks on right ventricular systolic pressure (RVSP) and on right ventricular (RV) hypertrophy in MCT-injected rats. (A) Representative tracings of RVSP of control rats, monocrotaline (MCT), MCT+vehicle (DMSO), and MCT+LASSBio-1366, respectively. (B) Right ventricular systolic pressure (RVSP). Oral treatment with LASSBio-1366 recovered this parameter. (C) Weight ratio RV/LV+S. Treatment with LASSBio-1366 decreased the RV hypertrophy. Each column represents the mean ± SEM (n=6). *P<0.05, **P<0.01, ***P<0.001 compared to control; †P<0.05 compared to MCT.